Brief: Ambu Narrows Organic Revenue Growth Guidance Based On Q3, Q4 Performance
Aug 31 (Reuters) - Ambu A/S AMBUb.CO :
* INTERIM REPORT FOR Q3 2022/23
* Q3 PERFORMANCE REFLECTED BY 23% GROWTH IN ENDOSCOPY
SOLUTIONS
AND 16% IN PULMONOLOGY
* NARROWS FULL-YEAR 2022/23 ORGANIC REVENUE GROWTH GUIDANCE
BASED
ON PERFORMANCE IN Q3 AND FIRST TWO MONTHS OF Q4
Source text for Eikon: ID:nGNE9hbNMS
Further company coverage: AMBUb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))
Recent news on Ambu A/S
See all newsBrief: Ambu Says Two Bronchoscopes Get FDA Clearance, CE Mark For Use In Pediatric Airway Procedures
Brief: Ambu Obtains Regulatory Clearances For Expanded GI Indication
UBS turns cautious on Ambu's targets, cuts to 'neutral'
Brief: Ambu Acquires TIMS Medical To Advance Endointelligence
Brief: Ambu Reports Q3 EBIT DKK 221 Mln